Global Keytruda Market

Keytruda Comprehensive Study by Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others), Distribution Channel (Retail, Online), End-User (Hospitals, Clinics) Players and Region - Global Market Outlook to 2030

Keytruda Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Keytruda
Pembrolizumab, also known as Keytruda, is a humanized antibody that is used to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer in cancer immunotherapy. It is administered with a gradual injection into a vein. Immunotherapy is a type of cancer treatment in which the body's natural immune system is boosted in order to combat cancer cells. It makes use of components created by the organization or components created in vitro in the laboratory. One of the major causes for the rise of these drugs in the market is the onset of cancer disorders. KEYTRUDA is an immunotherapy that works with your immune system to help fight specific tumors. It is neither chemotherapy or radiation therapy.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Keytruda market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amgen (United States), AstraZeneca (United Kingdom), F. Hoffman La-Roche (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (United States), Eli Lilly and Company (United States), Janssen Global Services, LLC (Belgium), Merck (United States), Novartis (Switzerland) and Pfizer (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Celldex Therapeutics (United States), Vitaeris (Canada) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Keytruda market by , Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer and Others) and Region.



On the basis of geography, the market of Keytruda has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel , the sub-segment i.e. Retail will boost the Keytruda market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Keytruda market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing demand for monoclonal antibodies and biosimilars

Market Growth Drivers:
Rise in Incidence of Cancer and Increase in Adoption of Immunotherapy Over Other Treatment Options

Challenges:
Lack of Awareness

Restraints:
Side Effects Related to Drugs and Complexities in Manufacturing

Opportunities:
Growth Opportunities in Untapped Markets and Development of affordable nanoparticles for deploying immunotherapies

Market Leaders and their expansionary development strategies
In March 2021, Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies.
In March 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.


Key Target Audience
Drug Manufacturers and Suppliers, Academic Research Institutes, Hospitals and Clinics, Research and Development (R&D) Companies and Regulatory Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Others
By Distribution Channel
  • Retail
  • Online

By End-User
  • Hospitals
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Incidence of Cancer
      • 3.2.2. Increase in Adoption of Immunotherapy Over Other Treatment Options
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Increasing demand for monoclonal antibodies and biosimilars
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Keytruda, by Application, Distribution Channel , End-User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Keytruda (Value)
      • 5.2.1. Global Keytruda by: Application (Value)
        • 5.2.1.1. Lung Cancer
        • 5.2.1.2. Breast Cancer
        • 5.2.1.3. Prostate Cancer
        • 5.2.1.4. Colorectal Cancer
        • 5.2.1.5. Others
      • 5.2.2. Global Keytruda by: End-User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Keytruda Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Keytruda: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffman La-Roche (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Janssen Global Services, LLC (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Keytruda Sale, by Application, Distribution Channel , End-User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Keytruda (Value)
      • 7.2.1. Global Keytruda by: Application (Value)
        • 7.2.1.1. Lung Cancer
        • 7.2.1.2. Breast Cancer
        • 7.2.1.3. Prostate Cancer
        • 7.2.1.4. Colorectal Cancer
        • 7.2.1.5. Others
      • 7.2.2. Global Keytruda by: End-User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Keytruda Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Keytruda: by Application(USD Million)
  • Table 2. Keytruda Lung Cancer , by Region USD Million (2018-2023)
  • Table 3. Keytruda Breast Cancer , by Region USD Million (2018-2023)
  • Table 4. Keytruda Prostate Cancer , by Region USD Million (2018-2023)
  • Table 5. Keytruda Colorectal Cancer , by Region USD Million (2018-2023)
  • Table 6. Keytruda Others , by Region USD Million (2018-2023)
  • Table 7. Keytruda: by End-User(USD Million)
  • Table 8. Keytruda Hospitals , by Region USD Million (2018-2023)
  • Table 9. Keytruda Clinics , by Region USD Million (2018-2023)
  • Table 10. South America Keytruda, by Country USD Million (2018-2023)
  • Table 11. South America Keytruda, by Application USD Million (2018-2023)
  • Table 12. South America Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 13. South America Keytruda, by End-User USD Million (2018-2023)
  • Table 14. Brazil Keytruda, by Application USD Million (2018-2023)
  • Table 15. Brazil Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 16. Brazil Keytruda, by End-User USD Million (2018-2023)
  • Table 17. Argentina Keytruda, by Application USD Million (2018-2023)
  • Table 18. Argentina Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 19. Argentina Keytruda, by End-User USD Million (2018-2023)
  • Table 20. Rest of South America Keytruda, by Application USD Million (2018-2023)
  • Table 21. Rest of South America Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 22. Rest of South America Keytruda, by End-User USD Million (2018-2023)
  • Table 23. Asia Pacific Keytruda, by Country USD Million (2018-2023)
  • Table 24. Asia Pacific Keytruda, by Application USD Million (2018-2023)
  • Table 25. Asia Pacific Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 26. Asia Pacific Keytruda, by End-User USD Million (2018-2023)
  • Table 27. China Keytruda, by Application USD Million (2018-2023)
  • Table 28. China Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 29. China Keytruda, by End-User USD Million (2018-2023)
  • Table 30. Japan Keytruda, by Application USD Million (2018-2023)
  • Table 31. Japan Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 32. Japan Keytruda, by End-User USD Million (2018-2023)
  • Table 33. India Keytruda, by Application USD Million (2018-2023)
  • Table 34. India Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 35. India Keytruda, by End-User USD Million (2018-2023)
  • Table 36. South Korea Keytruda, by Application USD Million (2018-2023)
  • Table 37. South Korea Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 38. South Korea Keytruda, by End-User USD Million (2018-2023)
  • Table 39. Taiwan Keytruda, by Application USD Million (2018-2023)
  • Table 40. Taiwan Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 41. Taiwan Keytruda, by End-User USD Million (2018-2023)
  • Table 42. Australia Keytruda, by Application USD Million (2018-2023)
  • Table 43. Australia Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 44. Australia Keytruda, by End-User USD Million (2018-2023)
  • Table 45. Rest of Asia-Pacific Keytruda, by Application USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Keytruda, by End-User USD Million (2018-2023)
  • Table 48. Europe Keytruda, by Country USD Million (2018-2023)
  • Table 49. Europe Keytruda, by Application USD Million (2018-2023)
  • Table 50. Europe Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 51. Europe Keytruda, by End-User USD Million (2018-2023)
  • Table 52. Germany Keytruda, by Application USD Million (2018-2023)
  • Table 53. Germany Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 54. Germany Keytruda, by End-User USD Million (2018-2023)
  • Table 55. France Keytruda, by Application USD Million (2018-2023)
  • Table 56. France Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 57. France Keytruda, by End-User USD Million (2018-2023)
  • Table 58. Italy Keytruda, by Application USD Million (2018-2023)
  • Table 59. Italy Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 60. Italy Keytruda, by End-User USD Million (2018-2023)
  • Table 61. United Kingdom Keytruda, by Application USD Million (2018-2023)
  • Table 62. United Kingdom Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 63. United Kingdom Keytruda, by End-User USD Million (2018-2023)
  • Table 64. Netherlands Keytruda, by Application USD Million (2018-2023)
  • Table 65. Netherlands Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 66. Netherlands Keytruda, by End-User USD Million (2018-2023)
  • Table 67. Rest of Europe Keytruda, by Application USD Million (2018-2023)
  • Table 68. Rest of Europe Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 69. Rest of Europe Keytruda, by End-User USD Million (2018-2023)
  • Table 70. MEA Keytruda, by Country USD Million (2018-2023)
  • Table 71. MEA Keytruda, by Application USD Million (2018-2023)
  • Table 72. MEA Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 73. MEA Keytruda, by End-User USD Million (2018-2023)
  • Table 74. Middle East Keytruda, by Application USD Million (2018-2023)
  • Table 75. Middle East Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 76. Middle East Keytruda, by End-User USD Million (2018-2023)
  • Table 77. Africa Keytruda, by Application USD Million (2018-2023)
  • Table 78. Africa Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 79. Africa Keytruda, by End-User USD Million (2018-2023)
  • Table 80. North America Keytruda, by Country USD Million (2018-2023)
  • Table 81. North America Keytruda, by Application USD Million (2018-2023)
  • Table 82. North America Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 83. North America Keytruda, by End-User USD Million (2018-2023)
  • Table 84. United States Keytruda, by Application USD Million (2018-2023)
  • Table 85. United States Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 86. United States Keytruda, by End-User USD Million (2018-2023)
  • Table 87. Canada Keytruda, by Application USD Million (2018-2023)
  • Table 88. Canada Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 89. Canada Keytruda, by End-User USD Million (2018-2023)
  • Table 90. Mexico Keytruda, by Application USD Million (2018-2023)
  • Table 91. Mexico Keytruda, by Distribution Channel USD Million (2018-2023)
  • Table 92. Mexico Keytruda, by End-User USD Million (2018-2023)
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Keytruda: by Application(USD Million)
  • Table 104. Keytruda Lung Cancer , by Region USD Million (2025-2030)
  • Table 105. Keytruda Breast Cancer , by Region USD Million (2025-2030)
  • Table 106. Keytruda Prostate Cancer , by Region USD Million (2025-2030)
  • Table 107. Keytruda Colorectal Cancer , by Region USD Million (2025-2030)
  • Table 108. Keytruda Others , by Region USD Million (2025-2030)
  • Table 109. Keytruda: by End-User(USD Million)
  • Table 110. Keytruda Hospitals , by Region USD Million (2025-2030)
  • Table 111. Keytruda Clinics , by Region USD Million (2025-2030)
  • Table 112. South America Keytruda, by Country USD Million (2025-2030)
  • Table 113. South America Keytruda, by Application USD Million (2025-2030)
  • Table 114. South America Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 115. South America Keytruda, by End-User USD Million (2025-2030)
  • Table 116. Brazil Keytruda, by Application USD Million (2025-2030)
  • Table 117. Brazil Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 118. Brazil Keytruda, by End-User USD Million (2025-2030)
  • Table 119. Argentina Keytruda, by Application USD Million (2025-2030)
  • Table 120. Argentina Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 121. Argentina Keytruda, by End-User USD Million (2025-2030)
  • Table 122. Rest of South America Keytruda, by Application USD Million (2025-2030)
  • Table 123. Rest of South America Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 124. Rest of South America Keytruda, by End-User USD Million (2025-2030)
  • Table 125. Asia Pacific Keytruda, by Country USD Million (2025-2030)
  • Table 126. Asia Pacific Keytruda, by Application USD Million (2025-2030)
  • Table 127. Asia Pacific Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 128. Asia Pacific Keytruda, by End-User USD Million (2025-2030)
  • Table 129. China Keytruda, by Application USD Million (2025-2030)
  • Table 130. China Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 131. China Keytruda, by End-User USD Million (2025-2030)
  • Table 132. Japan Keytruda, by Application USD Million (2025-2030)
  • Table 133. Japan Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 134. Japan Keytruda, by End-User USD Million (2025-2030)
  • Table 135. India Keytruda, by Application USD Million (2025-2030)
  • Table 136. India Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 137. India Keytruda, by End-User USD Million (2025-2030)
  • Table 138. South Korea Keytruda, by Application USD Million (2025-2030)
  • Table 139. South Korea Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 140. South Korea Keytruda, by End-User USD Million (2025-2030)
  • Table 141. Taiwan Keytruda, by Application USD Million (2025-2030)
  • Table 142. Taiwan Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 143. Taiwan Keytruda, by End-User USD Million (2025-2030)
  • Table 144. Australia Keytruda, by Application USD Million (2025-2030)
  • Table 145. Australia Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 146. Australia Keytruda, by End-User USD Million (2025-2030)
  • Table 147. Rest of Asia-Pacific Keytruda, by Application USD Million (2025-2030)
  • Table 148. Rest of Asia-Pacific Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Keytruda, by End-User USD Million (2025-2030)
  • Table 150. Europe Keytruda, by Country USD Million (2025-2030)
  • Table 151. Europe Keytruda, by Application USD Million (2025-2030)
  • Table 152. Europe Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 153. Europe Keytruda, by End-User USD Million (2025-2030)
  • Table 154. Germany Keytruda, by Application USD Million (2025-2030)
  • Table 155. Germany Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 156. Germany Keytruda, by End-User USD Million (2025-2030)
  • Table 157. France Keytruda, by Application USD Million (2025-2030)
  • Table 158. France Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 159. France Keytruda, by End-User USD Million (2025-2030)
  • Table 160. Italy Keytruda, by Application USD Million (2025-2030)
  • Table 161. Italy Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 162. Italy Keytruda, by End-User USD Million (2025-2030)
  • Table 163. United Kingdom Keytruda, by Application USD Million (2025-2030)
  • Table 164. United Kingdom Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 165. United Kingdom Keytruda, by End-User USD Million (2025-2030)
  • Table 166. Netherlands Keytruda, by Application USD Million (2025-2030)
  • Table 167. Netherlands Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 168. Netherlands Keytruda, by End-User USD Million (2025-2030)
  • Table 169. Rest of Europe Keytruda, by Application USD Million (2025-2030)
  • Table 170. Rest of Europe Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 171. Rest of Europe Keytruda, by End-User USD Million (2025-2030)
  • Table 172. MEA Keytruda, by Country USD Million (2025-2030)
  • Table 173. MEA Keytruda, by Application USD Million (2025-2030)
  • Table 174. MEA Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 175. MEA Keytruda, by End-User USD Million (2025-2030)
  • Table 176. Middle East Keytruda, by Application USD Million (2025-2030)
  • Table 177. Middle East Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 178. Middle East Keytruda, by End-User USD Million (2025-2030)
  • Table 179. Africa Keytruda, by Application USD Million (2025-2030)
  • Table 180. Africa Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 181. Africa Keytruda, by End-User USD Million (2025-2030)
  • Table 182. North America Keytruda, by Country USD Million (2025-2030)
  • Table 183. North America Keytruda, by Application USD Million (2025-2030)
  • Table 184. North America Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 185. North America Keytruda, by End-User USD Million (2025-2030)
  • Table 186. United States Keytruda, by Application USD Million (2025-2030)
  • Table 187. United States Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 188. United States Keytruda, by End-User USD Million (2025-2030)
  • Table 189. Canada Keytruda, by Application USD Million (2025-2030)
  • Table 190. Canada Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 191. Canada Keytruda, by End-User USD Million (2025-2030)
  • Table 192. Mexico Keytruda, by Application USD Million (2025-2030)
  • Table 193. Mexico Keytruda, by Distribution Channel USD Million (2025-2030)
  • Table 194. Mexico Keytruda, by End-User USD Million (2025-2030)
  • Table 195. Research Programs/Design for This Report
  • Table 196. Key Data Information from Secondary Sources
  • Table 197. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Keytruda: by Application USD Million (2018-2023)
  • Figure 5. Global Keytruda: by End-User USD Million (2018-2023)
  • Figure 6. South America Keytruda Share (%), by Country
  • Figure 7. Asia Pacific Keytruda Share (%), by Country
  • Figure 8. Europe Keytruda Share (%), by Country
  • Figure 9. MEA Keytruda Share (%), by Country
  • Figure 10. North America Keytruda Share (%), by Country
  • Figure 11. Global Keytruda share by Players 2023 (%)
  • Figure 12. Global Keytruda share by Players (Top 3) 2023(%)
  • Figure 13. Global Keytruda share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 16. Amgen (United States) Revenue: by Geography 2023
  • Figure 17. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 19. F. Hoffman La-Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffman La-Roche (Switzerland) Revenue: by Geography 2023
  • Figure 21. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 23. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 27. Janssen Global Services, LLC (Belgium) Revenue, Net Income and Gross profit
  • Figure 28. Janssen Global Services, LLC (Belgium) Revenue: by Geography 2023
  • Figure 29. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck (United States) Revenue: by Geography 2023
  • Figure 31. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 33. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer (United States) Revenue: by Geography 2023
  • Figure 35. Global Keytruda: by Application USD Million (2025-2030)
  • Figure 36. Global Keytruda: by End-User USD Million (2025-2030)
  • Figure 37. South America Keytruda Share (%), by Country
  • Figure 38. Asia Pacific Keytruda Share (%), by Country
  • Figure 39. Europe Keytruda Share (%), by Country
  • Figure 40. MEA Keytruda Share (%), by Country
  • Figure 41. North America Keytruda Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen (United States)
  • AstraZeneca (United Kingdom)
  • F. Hoffman La-Roche (Switzerland)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly and Company (United States)
  • Janssen Global Services, LLC (Belgium)
  • Merck (United States)
  • Novartis (Switzerland)
  • Pfizer (United States)
Additional players considered in the study are as follows:
Celldex Therapeutics (United States) , Vitaeris (Canada) , Others
Select User Access Type

Key Highlights of Report


Mar 2024 175 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Keytruda Market Quantitative research analysis
Global Keytruda Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amgen (United States), AstraZeneca (United Kingdom), F. Hoffman La-Roche (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (United States), Eli Lilly and Company (United States), Janssen Global Services, LLC (Belgium), Merck (United States), Novartis (Switzerland) and Pfizer (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing demand for monoclonal antibodies and biosimilars" is seen as one of major influencing trends for Keytruda Market during projected period 2023-2030.
The Keytruda market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Keytruda Market Report?

Have a Query? Click Here

Other Related Reports

Neuromuscular Blocking Drugs Comprehensive Study by Distribution Channel (Online, Offline), End-User (Hospitals, Clinics, Others), Drug Class (Pachycurares, Leptocurares) Players and Region - Global ...
$ 3500
Sarcopenia Supplement Comprehensive Study by Type (Protein Supplement, Vitamin D & Calcium Supplement, Vitamin B12 Supplement), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online ph...
$ 3500
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Comprehensive Study by CRO Service (Discovery, Preclinical, Clinical Service, Laboratory Service), CMO Service (Active Ph...
$ 3750
Roll Compactor Comprehensive Study by Type (• <30Kg/Hour, • 30 – 200Kg/Hour, • >200Kg/Hour), Sales Channel (Online, Offline), End User (Pharmaceutical, Food and Beverage, Chemical, Others) Players an...
$ 3500
VLP Vaccines Comprehensive Study by Virus (Covid-19, Zika, HIV, Adeno-Associated Virus, Hepatitis C), Form (Tablet, Injectables, Capsules, Others), End Use (Hospitals, Specialty Clinics), Vaccine (Li...
$ 3650
Antithyroid Drug Comprehensive Study by Type (Propylthiouracil, Methimazole), Application (Hospital, Specialty Clinics), Distribution Channels (Hospital Dispensary, Retail Pharmacy, Online Pharmacy) ...
$ 3500